Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.52

Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.52 and traded as low as $1.33. Spero Therapeutics shares last traded at $1.34, with a volume of 54,156 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Thursday, April 4th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a research report on Thursday, May 16th.

Spero Therapeutics Stock Up 0.8 %

The firm has a market cap of $72.35 million, a PE ratio of 3.12 and a beta of 0.64. The stock’s fifty day simple moving average is $1.47 and its two-hundred day simple moving average is $1.52.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.17). The business had revenue of $9.27 million during the quarter, compared to analysts’ expectations of $16.80 million. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. On average, equities research analysts anticipate that Spero Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in Spero Therapeutics during the first quarter valued at approximately $31,000. Acadian Asset Management LLC lifted its position in Spero Therapeutics by 56.8% during the third quarter. Acadian Asset Management LLC now owns 272,024 shares of the company’s stock valued at $327,000 after purchasing an additional 98,485 shares during the period. Murchinson Ltd. lifted its position in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares during the period. ADAR1 Capital Management LLC bought a new position in Spero Therapeutics in the fourth quarter valued at about $1,570,000. Finally, Vanguard Group Inc. boosted its position in Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the last quarter. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.